Abstract:Objectives: The purpose of this study was to retrospectively validate the prognostic value of revised 2018 FIGO stage IIIC Methods: This is a retrospective analysis of patients with cervical cancer in stage III of the revised 2018 FIGO Staging System who received standardized treatment from 2011 to 2014 at a cancer hospital. Multi-group comparisons were performed with the Kruskal-Wallis H test and chi-square test. Survival curves were calculated using the Kaplan-Meier method and the log-rank test. A Cox proportional hazard regression model was used for multivariable analysis. Results: A total of 418 women were included, 42(10.0%) stage IIIA, 120(28.7%) stage IIIB, 190(45.5%) stage IIIC1 and 66(15.8%) stage IIIC2, there was no significant difference in histological type, tumor differentiation, tumor size, type of radiotherapy, consolidation chemotherapy among the four groups (all, P > 0.05). The stage IIIC1 patients were younger compared to those with stage IIIA (P<0.001) and IIIB(P=0.01). On univariate survival analyses, the 2018 FIGO staging system was significantly associated with survival in stage III cervical cancer (P<0.001). Women with stage IIIC1 disease had significantly improved survival compared to those with stage IIIC2 (P<0.001); Survival of women with stage IIIC1 was similar compared to those IIIA (P=0.484) and IIIB (P=0.042) (5-year OS rates:54.1% for IIIC1, 43.3% for IIIA, 40.6% for IIIB, 23.1% for IIIC2). In a multivariable model, stage IIIC2 disease was independently associated with a two-fold increased mortality risk compared to stage IIIC1 (HR = 2.066, 95% CI: 1.438-2.969, P<0.001), 2.6-fold compared to stage IIIB (HR=2.606, 95% CI 1.752-3.877, P<0.001) or nearly 3-fold compared to stage IIIA (HR = 2.958, 95% CI 1.757-4.983, P<0.001). Survival of stage IIIC1 disease significantly differed based on T-stage (5-year OS rates:72.2% for T1 vs 54.1% for T2 vs 18.6% for T3, P<0.001). Patients with stage IIIC1 (T1) had better OS compared with stage IIIA (P=0.004) and IIIB (P<0.001); Patients with stage IIIC1(T3) had worse OS compared with stage IIIA and IIIB (both P=0.001). On multivariable analysis, T-stage remained an independent prognostic factor for survival in patients with 2018 FIGO stage IIIC1 (P<0.001). Stage IIIC1(T1) was independently associated with improved survival compared to stage IIIA (HR = 0.514, 95% CI 0.287-0.921, P=0.025) or stage IIIB disease (HR = 0.420, 95% CI 0.263-0.672, P<0.001). The best prognostic cut-off value of the number of metastatic pelvic lymph node (MPLNs) was 2 for stage IIIC1p(T1/T2a). Patients with >2 MPLNs had worse OS compared with those having <2 (5-year OS rates were 76% and 47.9%, respectively, P<0.001). Multivariate analyses demonstrated that the extent of MPLNs yield impact on OS(HR = 2.753, 95% CI 1.527-4.965, P=0.001). Conclusions: Patients with stage IIIC1 represent a heterogeneous population with a variable prognosis, using T stage and a cut-off value of 2 MPLNs could gain a better predict prognostic outcomes.

Clinical and Pathological Factors Related to the Prognosis of Chinese Patients with Stage Ⅰb to Ⅱb Cervical Cancer

[Analysis of Prognostic Factors in Patients with Cervical Squamous Cell Carcinoma of Stage Ib and IIa].

The Clinical and Prognostic Analysis of 363 Cases of Stage ⅠB1 ～ ⅡA2 Cervical Cancer

Analysis of Prognostic Factors of Ⅰ A～ Ⅱ B Squamous Carcinoma of the Cervix

The Prognosis of Patients with Stage Ib-IIb Node-Negative Cervical Carcinoma

Prognostic factors and survival of stage ⅠB-ⅡA cervical cancer

Prognostic analysis of stage IIIC1p cervical cancer patients

Prognostic Factors and Survival of Stage IB-IIA Cervical Cancer.

Clinical and pathological factors influencing the prognosis of patients with cervical cancer

Analysis of the clinicopothological factors affecting the prognosis of cervical squamous cell carcinoma

The significance of pelvic lymphadenectomy for stage I endometrial carcinoma.

Risk Factors and Prognosis of IB-IIB Cervical Carcinoma with Common Iliac Lymph Node Metastasis.

[Analysis of the Relationship Between Clinicopathological Features and Pelvic Lymph Node Metastasis in Patients with Early Stage Squamous Cell Carcinoma of the Uterine Cervix].

The Number of Positive Pelvic Lymph Nodes and Multiple Groups of Pelvic Lymph Node Metastasis Influence Prognosis in Stage IA-IIB Cervical Squamous Cell Carcinoma

Prognosis of Stage III Cervical Cancer: a Two-Way Outcome Study.

The prognostic factors for patients with stage Ⅰ_b cervical squamous cell carcinoma treated by radical hysterectomy and radiotherapy

Validation of the 2018 FIGO Staging System for Predicting the Prognosis of Patients with Stage IIIC Cervical Cancer

Influence of Clinical and Pathologic Parameters on Prognosis of Cervical Carcinoma in China

The Prognosis of Women with Stage IB1-IIB Node-Positive Cervical Carcinoma after Radical Surgery

A Surgery-based Comprehensive Treatment Improved Prognosis in Patients with Stage IIIC Cervical Squamous Carcinoma: A Single Center Retrospective Study

Validation of the prognostic value of the 2018 FIGO stage IIIC in patients with cervical cancer